In vitro and in vivo studies have demonstrated antiproliferative and proapoptotic actions of PPARγ agonists such as 15d-PGJ2 and thiazolidinediones (TZDs) thus suggesting that PPARγ could be a promising therapeutical target for the treatment of cancer [11, 14]. The gene discussed is PPARG; the disease is cancer.